Notes - Genentech

Sally Smith Hughes | February 9, 2026

Chapter 1: Inventing Recombinant DNA Technology

Two Scientists on Converging Paths

Modern biotechnology began in 1973 with the invention of recombinant DNA technology, a method for joining pieces of DNA in a test tube, cloning them in an organism, and expressing the code as a protein. The two inventors, Herbert Boyer and Stanley Cohen, initially designed the technique for basic research but immediately recognized its potential for producing substances like insulin and growth hormone.

Herbert Boyer, coming from a blue-collar background, became fascinated by restriction enzymes—bacterial enzymes that cut foreign DNA at unique, predictable sequences. He realized early on that these enzymes could be used for the precision cutting and mapping of DNA. Stanley Cohen, a physician-scientist at Stanford, specialized in plasmids, tiny rings of DNA that reproduce outside the main chromosome and often carry antibiotic resistance genes.

By 1972, Cohen had developed a system r inserting plasmid DNA into bacteria, but it was slow and inefficient because it relied on random shearing of the DNA. Simultaneously, Boyer’s lab isolated the EcoRI restriction enzyme, which created "sticky ends"—staggered cuts that allowed DNA fragments to bond with complementary strands like Velcro. This natural ability to create cohesive ends offered a massive leap in efficiency over the tedious chemical synthesis of artificial sticky ends being attempted by other labs at the time.

The Collaboration

Cohen and Boyer met at a plasmid conference in Honolulu in November 1972. During a brainstorming session over beer and sandwiches at a Waikiki delicatessen, they realized that Boyer’s enzyme could precisely sever a plasmid, allowing a second DNA fragment to be attached and then inserted into bacteria for cloning. This synergistic approach promised to solve the randomness and inefficiency of Cohen’s previous plasmid transfer experiments.

The resulting experiment in early 1973 was a, proving that engineered plasmids could replicate themselves and faithfully clone inserted foreign DNA. While many scientists later claimed the success was obvious once the biochemical methods were known, at the time it was not certain that chimeric DNA molecules containing components from different biological species could actually be cloned.

The final collaborative experiment involved cloning DNA from a frog (Xenopus laevis) into bacterial cells. The resounding success proved that the method could reliably clone complex animal genes in primitive bacteria, suggesting that the technology could be applied to any organism regardless of its position on the evolutionary scale. This achievement flung open the door to the productive study of human and animal genetics, which had previously been frustrated by the lack of a straightforward replication method.

Patenting and Politics

The potential for bacteria to be transformed into "factories" for pharmaceuticals caught the attention of the media and the Stanford Office of Technology Licensing. At the time, biomedical scientists rarely considered patenting, as discovery in this field was traditionally viewed as something that should be publicly available rather than restricted. Despite initial reservations about whether one could or should patent basic research, Cohen was persuaded that patents were a necessary means to encourage commercial development.

As the patenting process began, a heated political debate erupted regarding the safety of genetic engineering. Boyer’s disclosure at a 1973 conference that they had created novel combinations of antibiotic resistance genes triggered fears about engineered bacteria threatening human health. This led to the Asilomar Conference in 1975, where scientists attempted to self-regulate by devising safety guidelines to avoid government-imposed restrictions.

Critics, including prominent scientists like Paul Berg and Arthur Kornberg, attacked the effort to patent the technogy, charging that it attempted to privatize a basic biological discovery. This period was particularly stressful for Cohen, who believed that if scientists ("whales") did not maintain a low profile, they would be "harpooned" by political controversy.

Steps toward Commercialization

Despite the utilitarian strain in American science that research should benefit the public, the academic culture of the 1970s was inhospitable to professors forming deep ties with business. Cohen took a measured step by becoming a consultant for Cetus Corporation in 1975, viewing it as a way to advance industrial application without abandoning his academic orientation.

Boyer, meanwhile, remained focused on his lab at UCSF, which had become a virtual factory for plasmids and enzymes used by researchers worldwide. He speculated freely about the industrial prospects of recombinant DNA but had no initial intention of starting a company. He attempted to interest at least one drug company in exploring the technology for hormone synthesis, but the firm was not interested.

Boyer eventually tried to launch a research collaboration with a chemist in Germany to clone a synthetic gene for angiotensin II, a human hormone. However, the plan failed when the chemist decided to attempt the work independently in his own lab. This left Boyer without an avenue for carrying his commercial strategy further just as Bob Swanson was about to enter the scene.

Chapter 2: Creating Genentech

The founding of Genentech was an improbable alliance between a preoccupied professor and an unemployed venture capitalist, a partnership that eventually overcame industry skepticism and political controversy to launch the biotechnology sector.

Bob Swanson

Robert Arthur Swanson was driven by a remarkable ambition, instilled from a childhood where he was taught that each generation should surpass the last. Educated at MIT, he originally planned a career in the chemical industry but realized during a summer job that he "enjoyed people more than things". This led him to the Sloan School of Management, where he became enthralled by the "cottage industry" of venture capital, viewing it as a way to turn ideas into products while simultaneously building companies.

Swanson's "postdoctoral training" in finance took place at Citibank and then Kleiner & Perkins, where he was a junior partner. While monitoring an investment in Cetus Corporation, he first encountered the industrial potential of recombinant DNA (rDNA). While others at Cetus and Kleiner & Perkins were initially dismissive or cautious, Swanson recognized the technology as revolutionary. When he was eventually asked to leave Kleiner & Perkins at the end of 1975, he found himself scrimping on unemployment checks while obsessively cold-calling scientists to see if rDNA was ready for commercialization.

Founding Genentech

In January 1976, Swanson secured a ten-minute Friday afternoon meeting with Herbert Boyer at UCSF. Swanson arrived in a suit and tie—an "alien world of commerce" to the lab staff—to meet a disheveled professor in a leather vest. The ten-minute meeting stretched into three hours and several beers at a nearby tavern.

They discovered a shared belief in the commercial viability of rDNA, even though most prominent molecular biologists believed the technology was a decade or more away from a payoff. Naïveté was a critical ingredient in their success; Boyer later remarked that if they had truly understood the depth of the problems they would face, they might never have started.

On April 7, 1976, they signed incorporation papers for Genentech, a name Boyer coined as a contraction of "genetic engineering technology". Their initial salaries were modest: Swanson as president at $2,500 a month and Boyer as vice president at $1,000 a month.

Fundraising and Initial Strategy

Swanson’s first task was to secure financial backing. He targeted human insulin as the company's first project because it had a known amino acid sequence, a massive existing market ($100 million annually), and could potentially be produced more cheaply and safely than animal-derived insulin.

He returned to his former partners, Eugene Kleiner and Tom Perkins, with a six-page business plan. While Perkins was skeptical—asking, "Would God let you make a new form of life like this?"—he was impressed by Boyer’s clear, step-by-step explanation of the science. Kleiner & Perkins agreed to invest $100,000, the first venture capital stake in rDNA technology. This investment was considered highly speculative, with Perkins estimating a better than 50-50 chance of losing the entire stake.

Legal and Political Obstacles

Genentech faced immediate hurdles regarding intellectual property and safety regulations:

Licensing Struggles: Swanson desperately sought an exclusive license from Stanford and the University of California to practice rDNA technology under the pending Cohen-Boyer patent. He even offered 4,000 shares of stock as an incentive. However, Niels Reimers of Stanford's licensing office refused, concerned that an exclusive license for a controversial technology would be politically explosive.
Regulatory Maneuvers: To allay public fears and satisfy university officials, Swanson asserted that Genentech would comply with NIH guidelines for research, even though those guidelines technically only applied to federally funded research. He assured officials that Genentech would not conduct any "prohibited" experiments and would use standard containment facilities.
Offshore Contingency: Fearing that restrictive local ordinances in cities like Berkeley or Cambridge might stifle the work, Perkins and Swanson briefly considered moving Genentech offshore before deciding to stay in California to remain close to Boyer.

A Full Business Plan

By late 1976, Genentech was still a "virtual company"—it had no labs, no equipment, and no scientists of its own. Despite this, Swanson, Boyer, and Perkins drafted a 46-page business plan to secure a second round of financing.

This plan was a masterpiece of entrepreneurial promotion, claiming that "technical risks have been all but eliminated" and predicting the production of a recombinant therapeutic within six months. While reality was far more harrowing, this vision of becoming a fully integrated, independent pharmaceutical company remained Swanson's "grandiose and distant dream" that would eventually guide the firm’s development.

Chapter 3: Proving the Technology

While previous breakthroughs had demonstrated that DNA could be recombined and cloned, Genentech faced a unique hurdle: its core technology was raw, industrially untested, and lacked a single product in the pipeline. The company was essentially a "virtual" entity, and its survival rested on a high-stakes proof-of-concept experiment that would determine if the technology could actually produce a functional protein.

A Portentous Experiment

The path to proving the technology began with a collaboration between the Boyer lab and two scientists from the City of Hope: Arthur Riggs and Keiichi Itakura. At the time, chemical DNA synthesis—constructing genes from off-the-shelf chemicals—was a painstakingly exacting and error-prone procedure that yielded only minuscule, impure amounts of genetic material. The goal of the collaboration was to clone this man-made DNA in bacteria to allow the organisms to produce an unlimited, pure supply.

A significant practical advantage during these early experiments was the "gift" brought by Herbert Heyneker, a Dutch postdoc in Boyer’s lab, who arrived with a thermos filled with vials of purified enzymes. These enzymes were not yet commercially available and were essential for genetic recombination. In February 1976, the team successfully demonstrated that man-made genetic material could be "immortalized" through cloning and behave identically to natural DNA in a biological system. This achievement suggested that DNA synthesis would be the companion technology to make recombinant DNA a feasible industrial tool in the near term.

Switching Targets

While the ultimate goal was human insulin, the scientists realized that insulin’s double chain of fifty-one amino acids was too complex for the existing synthetic chemistry. Arthur Riggs made the strategic decision to switch the target to somatostatin, a brain hormone composed of only fourteen amino acids.

The scientific strategy was not to copy the human gene exactly, but to design a synthetic gene that bacteria would find compatible. There was deep skepticism in the scientific community; many prominent molecular biologists guessed that simple bacteria would be unable to "read" or express the genes of higher organisms. This experiment was a make-or-break attempt to see if bacteria could be programmed to become microscopic production sites for human-specified proteins.

Negotiating Research Agreements

To fund this research, Swanson had to move quickly to establish legal frameworks with the participating institutions. He often worked without an attorney to save on fees. The resulting agreements had long-lasting implications:

The University of California Agreement: The university held the title to patents and earned royalties, while Genentech received an exclusive license.
The City of Hope Agreement: In a notable departure from academic norms, Genentech was given exclusive ownership of all patents arising from the work, while the medical center received a 2 percent royalty on sales.
A Warning on Legal Complexity: Decades later, this City of Hope contract became the center of a massive lawsuit, eventually resulting in a $300 million judgment against Genentech over unpaid royalties from third-party licenses.

During this period, patent attorney Thomas Kiley began "indoctrinating" the scientists on the central importance of patenting. For a fledgling company, the basic "products" were the scientists' technical know-how and innovative power, which had to be monetized through intellectual property protection to justify investment.

Making Somatostatin

The project faced immediate pressure from Swanson, who was "extremely impatient and extremely anxious" because the firm’s survival and his own career were at stake. Despite his Intelligent questioning, the scientists found his constant monitoring and rigid schedules meaningless and annoying, as biological research rarely advances in a predictable business fashion.

The project hit a devastating low point when the first attempt to detect somatostatin in bacterial colonies failed completely. Swanson was so horrified by the prospect of his company "going down the tubes" that he checked himself into an emergency room for what turned out to be acute indigestion.

The scientists quickly pivoted, surmising that bacterial enzymes were destroying the tiny somatostatin protein as soon as it was made. They developed a new strategy: producing the hormone as a "tail" on a much larger bacterial protein. This hybrid protein was too large for the bacterial enzymes to degrade. The hormone remained "safely nonfunctional" until it was chemically clipped free after extraction.

In August 1977, this strategy worked, and the team successfully induced bacteria to manufacture a foreign mammalian protein. This represented the critically important validation of Genentech’s technology and bridged the gap between basic research and practical application.

Wider Issues

The success of the somatostatin experiment had immediate political and cultural consequences:

Political Maneuvering: Proponents of recombinant DNA research used the "scientific triumph" to lobby Congress against passing restrictive legislation, arguing that it was threshold evidence of a new industrial sector in medicine and agriculture.
Scientific Protocol Warnings: The announcement of the results at a Senate hearing and in press conferences before peer-reviewed publication drew sharp criticism from science editors who labeled the trend "gene cloning by press conference".
The "Entrepreneurial Biologist" Controversy: Herbert Boyer became a lightning rod for criticism. His colleagues at UCSF were in an uproar over his "wearing two hats," arguing that his direct, substantial association with a for-profit company was a betrayal of academic values.

Despite the internal academic turmoil, the experiment successfully convinced the pharmaceutical industry that genetic engineering could be commercially productive. While somatostatin itself would never be a commercial product for Genentech, it provided the verified model needed to target the "real" goal: human insulin.

Chapter 4: Human Insulin: Genentech Makes Its Mark

The transition from the somatostatin experiment to the human insulin project marked a shift from a basic-science proof-of-concept to a trial-by-fire test of industrial viability. While somatostatin had no clear market, human insulin was a high-stakes target with an existing multi-million dollar global market and established therapeutic value. This project was designed to prove that the company could produce complex, multi-chain proteins used in common medical practice before its initial funding ran out.

Seeking Corporate Contracts

Establishing long-term financing required moving beyond periodic infusions of venture capital and securing research and development agreements with established pharmaceutical firms. Early attempts to partner with Novo Industri and Hoechst failed because those companies remained skeptical that recombinant DNA technology could ever work as a reliable industrial process. This left Eli Lilly and Company, which held an 80 percent share of the North American insulin market, as the primary remaining option.

Lilly was motivated to explore genetic engineering because the traditional method of extracting insulin from animal pancreases was not expected to keep up with the growing diabetic population. Furthermore, human insulin was theorized to reduce allergic reactions occasionally caused by animal-derived versions. To protect its flagship product, Lilly began monitoring academic teams at Harvard and the University of California, San Francisco (UCSF), but eventually turned to the fledgling start-up for a more direct commercial alliance.

Procuring a Facility and Staff

In early 1978, the company transitioned from a "virtual" entity into a physical one by leasing a 10,000-square-foot section of an airfreight warehouse in South San Francisco. The location was chosen for its proximity to major research universities and Silicon Valley’s entrepreneurial infrastructure, as well as the city's lack of restrictive local ordinances regarding genetic research—a significant contrast to the political activism in Berkeley.

To signal industrial intent, the company hired a fermentation expert from Squibb & Sons and designated him as vice president of manufacturing before it even had a functional laboratory or a single resident scientist. The recruitment of scientific talent focused on junior researchers who were adept in the latest techniques but more willing to risk their careers on a start-up than tenured professors. Key additions included:

Dennis Kleid: An organic chemist with training in DNA synthesis and molecular biology.
David Goeddel: A driven young biochemist and passionate rock climber whose "do-or-die" mentality in Yosemite translated to a relentless work ethic in the lab, often toiling 20 hours a day.
Daniel Yansura: A specialist in DNA synthesis who was drawn by the challenge of pioneering applied research.

Genentech’s Human Insulin Project

The technical challenge of insulin was significantly greater than somatostatin because insulin is composed of two distinct amino acid chains—the A and B chains—comprising 51 amino acids total. The scientific strategy involved chemically synthesizing DNA fragments at the City of Hope, which were then ferried to the warehouse lab for assembly and cloning.

Because the warehouse laboratory was initially an empty shell, Goeddel and Kleid were forced to work in a "closet-size" lab provided by colleagues at the City of Hope. The team faced a "cutthroat" race against elite academic teams at Harvard and UCSF who were using a different method called complementary DNA (cDNA) cloning.

A non-obvious but decisive competitive advantage emerged from the 1976 NIH guidelines. These strict safety regulations applied to natural human genetic material but did not explicitly cover chemically synthesized DNA. While academic rivals were bogged down by mandatory high-containment biohazard requirements—even being forced to move their research to labs in France and England to escape U.S. restrictions—the warehouse scientists could work under ordinary laboratory conditions using their man-made DNA.

The technical breakthrough occurred in the early morning hours of August 21, 1978, when the isolated A and B chains were successfully reconstituted into a complete, biologically active human insulin molecule.

The Eli Lilly Contract

Four days after the laboratory success, a multimillion-dollar, twenty-year R&D agreement was signed with Eli Lilly. The deal included:

Upfront Licensing: A $500,000 fee for exclusive worldwide rights to manufacture and market the insulin using Genentech's technology.
Royalties: An 8 percent total royalty rate on product sales (6 percent to Genentech, 2 percent to City of Hope), which was considered exorbitant for the time.
Research Benchmarks: A series of rigorous scientific milestones Genentech was required to meet by specific dates to receive progress payments.

A practical warning for the scientists was that these benchmarks meant their salaries and the firm's survival were now tied to an industrial timetable. Failure to meet a milestone could allow Lilly to terminate the agreement. This contract established a new organizational model for the industry: the big company–small company alliance, where a small, fleet firm conducts the innovative, high-risk research and the large partner handles the expensive stages of drug development, clinical trials, and global marketing.

Publicity and Expansion

The announcement of the insulin achievement was choreographed through a press conference designed to trigger investor interest, despite the fact that the research had not yet been peer-reviewed or published. This led to criticism regarding "gene cloning by press conference".

A significant internal conflict arose over trade secrecy versus open publication. Management initially wanted to keep experimental findings secret to protect intellectual property, but a policy was eventually established that scientists would be encouraged to publish in scholarly journals provided that patent applications were filed first. This compromise was vital for recruiting high-caliber talent from academia who craved peer recognition.

Following the success, the company successfully recruited the UCSF postdocs Axel Ullrich and Peter Seeburg, who had felt denied of scientific credit and patent royalties at the university. By the end of 1978, the staff had grown to twenty-six, and the company had established its first egalitarian, flexible research structure focused entirely on making marketable products. This validation by a major drug firm like Lilly "put Genentech on the map," providing the credibility needed to attract future financing and signaling the arrival of the biotechnology sector.

Chapter 5: Human Growth Hormone: Shaping a Commercial Future

Competing for Human Growth Hormone

Following the milestone of insulin, the focus shifted immediately to human growth hormone (HGH), a target that had been part of the research plan from the company’s inception. The HGH molecule presented a much greater challenge than insulin because it is nearly four times larger, consisting of 191 amino acids compared to insulin’s 51. At the time, the primary commercial supplier was KabiVitrum, a Swedish government-owned firm that extracted the hormone from the pituitary glands of human cadavers. Because the supply of human pituitaries was limited, the drug was scarce and costly, used only for the most severe cases of pituitary dwarfism. KabiVitrum saw recombinant DNA as a way to produce a more abundant, profitable supply and potentially save the firm from bankruptcy.

A formal long-term research and development agreement was signed on August 1, 1978, making it the first such contract between an established corporation and a genetic engineering firm. Kabi agreed to pay $1 million for engineered bacteria and received exclusive foreign marketing rights, while the U.S. market was to be shared.

The scientific race involved a intense rivalry with the University of California, San Francisco (UCSF). Peter Seeburg, a talented postdoc at UCSF, had already cloned rat growth hormone and was being recruited by both Genentech and Eli Lilly. On New Year’s Eve 1978, in an event known as the "midnight raid," Seeburg and colleague Axel Ullrich entered their UCSF lab to remove biological samples, including a human growth hormone complementary DNA (cDNA) clone, and transported them to the Genentech facility. This act led to years of legal disputes over the ownership of research materials and allegations of falsified data to hide the UCSF origin of certain clones.

Because the HGH gene was too large to synthesize purely through chemical means, the scientists developed a highly original semi-synthetic approach. They constructed a short synthetic segment for the front of the gene and linked it to a longer cDNA segment coding for the rest of the protein. After months of Seeburg struggling with personal issues and research stalls, Dave Goeddel took over the project. In July 1979, Goeddel achieved success, creating a complicated gene that induced bacteria to churn out pure human growth hormone in quantity—estimated at 200,000 molecules per bacterium. Unlike previous experiments, this resulted in a pure, freestanding substance rather than a fusion protein, suggesting the technology could be applied to even more complex human proteins.

Moving toward Corporate Integration

A strategic shift occurred as the company looked toward its long-term survival: the goal was no longer just to be a contract research boutique but to become a fully integrated, independent pharmaceutical company. The belief was that the only way to capture the full monetary value of research was to manufacture and market the drugs internally.

HGH was the ideal project to test this "integration" strategy because it had no entrenched competition in the U.S. and was distributed through a small, specific group of pediatric endocrinologists. This meant the firm could avoid the massive costs usually associated with large-scale drug promotion and distribution. In 1980, exclusive U.S. marketing rights for recombinant HGH were licensed back from Kabi. While HGH was initially viewed as a small-market product, expectations grew that it could eventually treat a wider variety of conditions, such as wounds and bone fractures, potentially creating a $100 million market.

Scaling Up Insulin and Growth Hormone

Translating a laboratory-scale success into an industrial manufacturing process presented entirely new hurdles. The process required engineering organisms to purified and expressed unique proteins in massive quantities for clinical studies. During this phase, the firm collided with the National Institutes of Health (NIH) guidelines, which at the time limited recombinant cultures to a ten-liter maximum.

To meet benchmarks for Eli Lilly, the company began cultivating sixty-liter batches, arguing that the medical needs of the diabetic population outweighed restrictive federal policies. By 1980, federal regulatory clamps loosened, and the NIH began permitting larger-scale experiments on a case-by-case basis. This cleared the way for Eli Lilly to begin human clinical trials for insulin (marketed as Humulin), which received FDA approval in October 1982—the first recombinant pharmaceutical for human use to reach the market.

The development of HGH (marketed as Protropin) took a more erratic path. Early clinical trials in employees were halted after recipients suffered fever and soreness due to bacterial contaminants. However, an unexpected tragedy accelerated its approval: in 1985, several adults died of Creutzfeldt-Jakob disease after receiving cadaver-derived growth hormone. As the FDA pulled the natural hormone from the market due to contamination risks, they dropped previous reservations about the recombinant version. Protropin was approved on October 18, 1985, and achieved $2 billion in sales within twenty years.

Corporate Expansion

The late 1970s saw rapid expansion in both project scope and management depth. New projects were launched on interferon, animal growth hormone, and a hepatitis B vaccine. To handle this growth, the first full management team was assembled, including Bill Young from Eli Lilly to lead manufacturing and Tom Kiley as general legal counsel.

The corporate structure was famously flexible and informal; business charts often failed to accurately reflect the actual organization, which relied on improvisation and quick action. Leadership insisted on achieving profitability early, even as a start-up, and by 1979, the company reported it was operating "in the black". Management style was characterized as "management-by-walking-around," with leadership frequently appearing in the labs to act as cheerleaders or scientific sounding boards.

An Emerging Culture

A unique "recombinant culture" developed, blending academic values with commercial objectives. Scientists were encouraged to publish in peer-reviewed journals to gain recognition and status, which also helped the firm recruit top-tier talent from universities. However, these academic pursuits were always balanced against the mandate to produce strong patents and marketable products.

The internal atmosphere was defined by high energy, male adrenaline, and juvenile pranks. Friday afternoon beer fests, known as "Ho-hos," were egalitarian and often raucous events where management and staff mixed on a first-name basis. While the environment was incredibly productive and committed, it was also described as "macho city," reflecting the less inclusive cultural norms of the 1970s. Despite these blemishes, the culture fostered a sense of belonging and conviction that the firm was doing something revolutionary.

Chapter 6: Wall Street Debut

Biomania

By the late 1970s, a phenomenon known as "Biomania" swept through the financial and corporate worlds, driven by intense media hype that described microbes as "superbug" factories capable of producing everything from medicine to energy. This era was characterized by a massive influx of capital; by late 1979, venture capital and corporate investment in industrial biology totaled an estimated $150 million.

The national environment shifted significantly during this period to favor high technology. Policy makers recognized that onerous regulations and restrictive taxes were stifling American innovation. Consequently, several pro-business initiatives were passed to stimulate the economy:

Tax Incentives: Congress cut the long-term capital gains tax in 1978 and relaxed "prudent man" rules in 1979, allowing pension funds to invest in high-risk ventures.
Technology Transfer: The Stevenson-Wydler Technology Innovation Act and the Bayh-Dole Patent and Trademark Act of 1980 encouraged the patenting and licensing of federally funded research, facilitating the transfer of university discoveries to the private sector.
Regulatory Relaxation: Previous anxieties regarding biohazards were replaced by expectations of practical benefits, leading the NIH and the Recombinant DNA Advisory Committee (RAC) to grant industry more latitude, such as permitting large-scale manufacturing cultures.

Exit Strategies

As a venture-capital-supported start-up, Genentech was required to provide a financial return to its investors through an "exit strategy"—either a buyout or an Initial Public Offering (IPO).

Initial attempts at a buyout were unsuccessful:

Johnson & Johnson: Despite an elaborate dinner at Tom Perkins’ estate, J&J executives could not determine how to value a company with no history of earnings and were unsure how to integrate large-molecule technology into their traditional pharmaceutical model.
Eli Lilly: A proposed selling price of $100 million was rejected. Lilly was perceived to have a conservative "not invented here" mentality and likely felt they already had what they needed: the human insulin clones.

Following these failures, Perkins advocated for an IPO to "suck up all the oxygen" in the field and establish Genentech as the undisputed leader before competitors like Cetus could act.

Interferon: The New Wonder Drug?

In 1980, interferon was the "sexiest" project in biotechnology, heralded by the media as a potential miracle cure for cancer. Genentech had initially viewed it as too risky because its protein sequence was unknown, but after the growth hormone success, they felt ready to tackle it.

Strategic Alliances: Genentech signed a formal agreement with Hoffmann–La Roche in January 1980. Genentech needed Roche’s financial backing and clinical experience, while Roche provided crucial interferon-producing cell lines.
Scientific Achievement: Despite intense competition from Biogen, Genentech and Roche announced the production of pure leukocyte and fibroblast interferons in June 1980, achieving higher yields than previously reported.
Scaling Up: The RAC permitted Genentech to produce interferon in 600-liter batches, significantly exceeding the original ten-liter limit and fueling rumors of an imminent public offering.

Run-Up to an Initial Public Offering

Staging an IPO for Genentech was a radical departure from conventional business practice because the company had no products on the market and no substantial sales revenues.

A significant internal conflict arose between the founders:

Swanson’s Resistance: He feared the rigorous SEC disclosure requirements would force Genentech to reveal sensitive contractual and technical secrets to competitors.
Perkins’ Persistence: He argued that the market timing was perfect and that the company needed massive capital to become a fully integrated pharmaceutical firm.
The Deciding Vote: When pushed to choose between his partners, Herbert Boyer wily responded, "I always vote with my friends," effectively breaking the ice and leading to the decision to go public.

Legal Impediments

Two major legal hurdles threatened to derail the IPO:

Diamond v. Chakrabarty: A Supreme Court case debated whether living organisms could be patented. A negative ruling would have destroyed Genentech’s ability to protect its primary assets. In June 1980, the Court ruled 5-4 that "anything under the sun made by man" is patentable, a decision that became a cornerstone of biotech law.
The UCSF Dispute: The University of California threatened legal action over the "midnight raid" in which Axel Ullrich and Peter Seeburg removed biological materials from UCSF for Genentech’s use. To prevent investors from being spooked, Genentech made a $350,000 settlement payment to the university just months before the offering.

The IPO

On October 14, 1980, Genentech (NASDAQ: GENE) made one of the most spectacular debuts in stock market history.

Market Frenzy: The share price skyrocketed from $35 to $80 within the first minute of trading, eventually peaking at $89.
Capital Raised: The offering raised over $36 million, valuing the company at approximately $532 million.
Wealth Generation: Boyer and Swanson each became instant paper multimillionaires, with profits of nearly $70 million. Even a former graduate student, Richard Scheller, found his shares worth over $1 million.
A "Million-Dollar Rabbit": In a cautionary example of market volatility, Axel Ullrich sold 800 shares before the IPO to buy a used VW Rabbit for $8,000; those same shares were worth over $1 million shortly after the company went public.

The IPO transformed the image of the molecular biologist into that of the entrepreneurial scientist, proving that genetic engineering could be a source of immense profit and launching a gold rush that inspired the creation of dozens of new biotechnology firms.